Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021

SKU ID : DEL-19306970 | Publishing Date : 12-Oct-2021 | No. of pages : 60

Detailed TOC of Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021

Introduction
Executive Summary
Antisense Oligonucleotide Therapeutics: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Cobitolimod: InDex Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Prexigebersen: Bio-Path Holdings
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
• Comparative Analysis
ALG-020572: Aligos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Antisense Oligonucleotide Therapeutics Key Companies
Antisense Oligonucleotide Therapeutics Key Products
Antisense Oligonucleotide Therapeutics- Unmet Needs
Antisense Oligonucleotide Therapeutics- Market Drivers and Barriers
Antisense Oligonucleotide Therapeutics- Future Perspectives and Conclusion
Antisense Oligonucleotide Therapeutics Analyst Views
Antisense Oligonucleotide Therapeutics Key Companies
Appendix

List of Figures, Tables and Charts Available in Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021

Table 1 Total Products for Antisense Oligonucleotide Therapeutics
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

Keyplayers in Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021

• Ionis Pharmaceuticals
• Secarna Pharmaceuticals
• Aro Biotherapeutics
• NeuBase Therapeutics
• Bio-Path Holdings, Inc.
• Scopus Biopharma
• Dyne Therapeutics
• CAMP4 Therapeutics
• Pulmotect
• GeneTx Biotherapeutics
• Aligos Therapeutics
• WaVe life Sciences